Results 111 to 120 of about 9,833 (206)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

Therapeutics and Clinical Risk Management, 2013
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Affairs Department, Beijing Novartis Pharma Co, Ltd, Beijing, People's Republic of ChinaAbstract: Vildagliptin is a selective and potent dipeptidyl ...
Pan CY, Wang XL
doaj  

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). [PDF]

Cureus
Kalra SSS, Sadasivam B, Najmi A, Chaurasia JK.   +3 more
europepmc   +1 more source

Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. [PDF]

Cureus
Sanghvi A, Warrier S.
europepmc   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting [PDF]

, 2015

core   +1 more source

Correction: Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity. [PDF]

Sci Rep
Samad A, Shahid S, Mansoor S, Afzal S, Javed M, Zidan A, Shoaib A, Jaber F, Iqbal S, Saad M, Mahmood S, Awwad NS, Ibrahium HA.   +12 more
europepmc   +1 more source

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent [PDF]

, 2015

core   +1 more source

Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. [PDF]

Pharmaceuticals (Basel)
Pedrero AC, Aldea-Perona A.
europepmc   +1 more source

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source